AN INVESTMENT OPPORTUNITY WORTH CONSIDERING

CURRENT INVESTORS

Backed by the Development Bank of Wales and Longbow Capital LLP, Calon has attracted over £15 million in equity investment.

Other investors include high net worth individuals in the UK and Germany as well as corporate and employee investors.

Between 2022 and 2023, Calon is seeking to raise new investment to fund clinical studies of the MiniVAD™ in the USA and Europe. Calon is targeting US FDA Early Feasibility Study (EFS) in 2024 to begin the process for US FDA Approvals. CE Mark and UK Regulatory approvals shall also commence during this time.

Many UK individual investors into Calon up to this point have invested under the Enterprise Investment Scheme and it is expected that future investment rounds will be EIS approved.

For further information on Calon and how to invest, please click here.